Spyre Therapeutics, a clinical-stage biotech innovating long-acting monoclonal antibodies for inflammatory bowel disease (IBD) and rheumatic diseases, released positive interim data on SPY001 from its ongoing SKYLINE Phase 2 trial. The company advanced SPY230 into Part B of the trial and exercises licensing options expanding its portfolio. Supported by a robust cash position post a $435 million equity raise, Spyre is well-capitalized to fuel its development programs targeting α4β7 integrin, TL1A, and IL-23 pathways. Its next-generation antibody engineering focuses on enhanced pharmacokinetics enabling quarterly or biannual dosing, potentially reshaping treatment paradigms in immune-mediated diseases.